

## Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross® has confirmed that the shortage for Taro-Carbamazepine 20 mg/ml Oral Suspension (DIN 02367394) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **August 28, 2024**. The following grouping was removed from the Critical Supply Product List **July 29, 2024**.

### CARBAMAZEPINE

#### 20 MG / ML ORAL SUSPENSION

00002367394	TARO-CARBAMAZEPINE	TAR	\$ 0.0802
00002194333	TEGRETOL	NOV	\$ 0.0900

Alberta Blue Cross has confirmed that the shortage for Apo-Timop 0.5% Ophthalmic Solution (DIN 00755834) and Jamp-Timolol 0.5% Ophthalmic Solution (DIN 02447800) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 5, 2024**. The following grouping was removed from the Critical Supply Product List **August 6, 2024**.

### TIMOLOL MALEATE

#### 0.5 % OPHTHALMIC SOLUTION

00000755834	APO-TIMOP	APX	\$ 1.2140
00002447800	JAMP-TIMOLOL	JPC	\$ 1.2140
00002166720	SANDOZ TIMOLOL MALEATE	SDZ	\$ 1.2140
00000451207	TIMOPTIC	ELV	\$ 4.4533

Alberta Blue Cross has confirmed that the shortage for pms-Buprenorphine/Naloxone 8 mg/2 mg Sublingual Tablet (DIN 02424878) and Teva-Buprenorphine/Naloxone 8 mg/2 mg Sublingual Tablet (DIN 02453916) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 9, 2024**. The following grouping was removed from the Critical Supply Product List **August 9, 2024**.

### BUPRENORPHINE HCL/ NALOXONE HYDROCHLORIDE DIHYDRATE

#### 8 MG / 2 MG SUBLINGUAL TABLET

00002424878	PMS-BUPRENORPHINE/NALOXONE	PMS	\$ 2.3650
00002453916	TEVA-BUPRENORPHINE/NALOXONE	TEV	\$ 2.3650
00002295709	SUBOXONE	IUK	\$ 4.8293

continued next page

continued from previous page

Alberta Blue Cross has confirmed that the shortage for Apo-Alfuzosin 10 mg Sustained-Release Tablet (DIN 02315866) and Auro-Alfuzosin 10 mg Sustained-Release Tablet (DIN 02443201) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 12, 2024**. The following grouping was removed from the Critical Supply Product List **August 13, 2024**.

## ALFUZOSIN HCL

### 10 MG SUSTAINED-RELEASE TABLET

00002447576	ALFUZOSIN	SIV	\$ 0.2601
00002519844	ALFUZOSIN	SNS	\$ 0.2601
00002315866	APO-ALFUZOSIN	APX	\$ 0.2601
00002443201	AURO-ALFUZOSIN	AUR	\$ 0.2601
00002304678	SANDOZ ALFUZOSIN	SDZ	\$ 0.2601
00002245565	XATRAL	SAV	\$ 1.0900

## Removal of temporary benefit from the ADBL

Due to the shortage of pms-Ipratropium 0.03% Nasal Spray (DIN 02239627), **Ipravent 0.06% Nasal Spray (DIN 02246084)** manufactured by AA Pharma Inc. was added as a temporary benefit for the ADBL.

Alberta Blue Cross has confirmed that the shortage for pms-Ipratropium 0.03% Nasal Spray (DIN 02239627) has been resolved.

**Ipravent 0.06% Nasal Spray (DIN 02246084)** will no longer be considered a temporary benefit for the ADBL **after September 1, 2024**. The above grouping was removed from the Critical Supply Product List **August 12, 2024**.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit [ab.bluecross.ca/providers/pharmacy-home.php](http://ab.bluecross.ca/providers/pharmacy-home.php)

